PMID- 26087729
OWN - NLM
STAT- MEDLINE
DCOM- 20160414
LR  - 20220410
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 243
DP  - 2015 Jun
TI  - CASE REPORT OF IRRITABLE BOWEL SYNDROME RESPONDING TO OMALIZUMAB.
PG  - 42-5
AB  - Irritable bowel syndrome (IBS) is the most commonly diagnosed gastrointestinal 
      condition manifested by chronic abdominal pain and altered bowel habits in the 
      absence of any organic cause. While 10% - 20% of the population has IBS, only  approximately  
      25% of patients with IBS seek professional health care. Due to IBS multifactorial 
      etiology, there is no single therapeutic option available with a satisfactory 
      efficacy; therefore, patients frequently express a high level of frustration with 
      their current therapies. We present a case of the 42 year-old woman with IBS, who 
      was administered Omalizumab (a recombinant DNA-derived humanized IgG1 monoclonal 
      antibody which specifically binds to free human immunoglobulin E (IgE) in the 
      blood) doe to concomitant antihistamine resistant chronic spontaneous urticaria 
      and experienced significant improvement in overall IBS symptoms. If our 
      observation will be confirmed in prospective randomized studies, Omalizumab may 
      turn out to be a useful pharmacological tool for this common disorder.
FAU - Magen, E
AU  - Magen E
AD  - Ben Gurion University of Negev, Barzilai Medical Center, Allergy and Clinical 
      Immunology Unit, Medicine B Department, Ashkelon; Leumit Health Services, Israel; 
      Tbilisi State Medical University, Microbiology and Immunology Department, 
      Georgia.
FAU - Chikovani, T
AU  - Chikovani T
AD  - Ben Gurion University of Negev, Barzilai Medical Center, Allergy and Clinical 
      Immunology Unit, Medicine B Department, Ashkelon; Leumit Health Services, Israel; 
      Tbilisi State Medical University, Microbiology and Immunology Department, 
      Georgia.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
RN  - 0 (Antibodies, Monoclonal)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Abdominal Pain/*drug therapy/pathology
MH  - Adult
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Irritable Bowel Syndrome/*drug therapy/physiopathology
MH  - Omalizumab/*administration & dosage
EDAT- 2015/06/20 06:00
MHDA- 2016/04/15 06:00
CRDT- 2015/06/20 06:00
PHST- 2015/06/20 06:00 [entrez]
PHST- 2015/06/20 06:00 [pubmed]
PHST- 2016/04/15 06:00 [medline]
PST - ppublish
SO  - Georgian Med News. 2015 Jun;(243):42-5.